Lipocine
LPCN
26 hedge funds and large institutions have $13.1M invested in Lipocine in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.
766% more capital invested
Capital invested by funds: $1.51M → $13.1M (+$11.6M)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
19.59% more ownership
Funds ownership: 9.77% → 29.36% (+20%)
18% more funds holding
Funds holding: 22 → 26 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$878K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$671K |
| 3 |
PAP
Persistent Asset Partners
Hong Kong
|
+$237K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$185K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$54.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$73.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$40.7K |
| 3 |
Barclays
London,
United Kingdom
|
-$26.8K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$7.23K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $417 | +$10 | +3 | +6% |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$40.7K | -14,247 | Closed |
|
|
28
Barclays
London,
United Kingdom
| – | -$26.8K | -9,412 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$3.33K | -1,170 | Closed |
|
30
Citigroup
New York
| – | -$9 | -3 | Closed |
|
LPCN Hedge Fund Activity: Q4 2025 in Review
26 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2025, worth a combined $13.1M — up 766% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LPCN positions and 4 closed out — a net gain of 4 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Diadema Partners, opening a new position worth an estimated $878K. The largest seller was Susquehanna International Group, cutting an estimated $73.5K.
- 26 institutional investors held Lipocine (LPCN) as of Q4 2025, up from 22 in Q3 2025.
- Funds reported $13.1M of Lipocine stock for Q4 2025, up 766% quarter-over-quarter.
- 8 funds opened new Lipocine positions in Q4 2025 and 4 closed out, a net change of +4 holders.
- The largest Lipocine buyer in Q4 2025 was Diadema Partners, an estimated $878K added.
- The largest Lipocine seller in Q4 2025 was Susquehanna International Group, an estimated $73.5K sold.
Based on aggregated 13F filings for Q4 2025.